• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

1,130
108
74
70
68

COUNTRY

69
22
16
10
9

CATEGORIES

  • 574
  • 118
  • 550
  • 75
  • 526
  • 43
  • 505
  • 18
  • 18
  • 23

PRICE

879
1,165
1,600
2,946

PUBLISHED

152
239
685
2,946

PRODUCT TYPE

2,375
494
67
7
1
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE

IVD Procedure Volume and Pricing Analysis

IVD Procedure Volume and Pricing Analysis This report examines the global procedure volumes for IVD and laboratory tests. It covers only commercialized tests, specifically excluding those that are...

January 2013
FROM
Global Lung Cancer Therapeutics Market 2012-2016 Global Lung Cancer Therapeutics Market 2012-2016 - Product Thumbnail Image

Global Lung Cancer Therapeutics Market 2012-2016

TechNavio's analysts forecast the Global Lung Cancer Therapeutics market to grow at a CAGR of 13.26 percent over the period 2012-2016. One of the key factors contributing to this market growth is the...

January 2013
FROM
Global Non-small Cell Lung Cancer Drugs Market 2012-2016 Global Non-small Cell Lung Cancer Drugs Market 2012-2016 - Product Thumbnail Image

Global Non-small Cell Lung Cancer Drugs Market 2012-2016

TechNavio's analysts forecast the Global Non-small Cell Lung Cancer market to grow at a CAGR of 2.77 percent over the period 2012-2016. One of the key factors contributing to this market growth is the...

January 2013
FROM

Melanoma Global Clinical Trials Review, H1, 2013

Melanoma Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Melanoma Global Clinical Trials Review, H1, 2013" provides data on the Melanoma clinical trial scenario. This report...

January 2013
FROM

Sezary Syndrome Global Clinical Trials Review, H1, 2013

Sezary Syndrome Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Sezary Syndrome Global Clinical Trials Review, H1, 2013" provides data on the Sezary Syndrome clinical trial...

January 2013
FROM

Bone Metastasis Global Clinical Trials Review, H1, 2013

Bone Metastasis Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Bone Metastasis Global Clinical Trials Review, H1, 2013" provides data on the Bone Metastasis clinical trial...

January 2013
FROM

Global Cancer Biomarkers Market 2012-2016

TechNavio's analysts forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.22 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing...

January 2013
FROM

Cardiac Pacing, Defibrillation and Resynchronization. A Clinical Approach. 3rd Edition

As our population ages and multiple factors contribute to an increased prevalence of cardiovascular disease, more patients than ever before will be candidates for implantable devices as part of their...

January 2013

World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas)

Molecular diagnostics is becoming a dominant platform in clinical medicine and represents one of the fastest growing segments of the IVD market.  As analyst Shara Rosen, R.T., MBA. details, in recent...

January 2013
FROM
Cancer Peptides: From First-in-Class to Best-in-Class? Cancer Peptides: From First-in-Class to Best-in-Class? - Product Thumbnail Image

Cancer Peptides: From First-in-Class to Best-in-Class?

This report gives you a new and unique way of stratifying and analyzing the global peptide pipeline in cancer towards personalized medicine and presents actionable analysis which allows you to discover:...

January 2013
FROM
Triple Analysis: Breast Cancer, Colorectal Cancer and Peptides Triple Analysis: Breast Cancer, Colorectal Cancer and Peptides - Product Thumbnail Image

Triple Analysis: Breast Cancer, Colorectal Cancer and Peptides

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Colorectal Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated...

January 2013
FROM
Triple Analysis: Breast Cancer, Leukemia and Peptides Triple Analysis: Breast Cancer, Leukemia and Peptides - Product Thumbnail Image

Triple Analysis: Breast Cancer, Leukemia and Peptides

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Leukemia and by the compound strategy of Peptides. Each of these three individual parts is evaluated according...

January 2013
FROM
Triple Analysis: Breast Cancer, Lymphoma and Peptides Triple Analysis: Breast Cancer, Lymphoma and Peptides - Product Thumbnail Image

Triple Analysis: Breast Cancer, Lymphoma and Peptides

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lymphoma and by the compound strategy of Peptides. Each of these three individual parts is evaluated according...

January 2013
FROM
Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Peptides Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Peptides - Product Thumbnail Image

Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Peptides

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Pancreatic Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated...

January 2013
FROM
Triple Analysis: Lymphoma, Pancreatic Cancer and Peptides Triple Analysis: Lymphoma, Pancreatic Cancer and Peptides - Product Thumbnail Image

Triple Analysis: Lymphoma, Pancreatic Cancer and Peptides

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated...

January 2013
FROM
Triple Analysis: Lymphoma, Angiogenesis and Peptides Triple Analysis: Lymphoma, Angiogenesis and Peptides - Product Thumbnail Image

Triple Analysis: Lymphoma, Angiogenesis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides)....

January 2013
FROM
Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides - Product Thumbnail Image

Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Peptides. Each...

January 2013
FROM
Triple Analysis: Angiogenesis, Antibodies and Peptides Triple Analysis: Angiogenesis, Antibodies and Peptides - Product Thumbnail Image

Triple Analysis: Angiogenesis, Antibodies and Peptides

This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Angiogenesis and by the two compound strategies of Antibodies and Peptides. Each of these three individual...

January 2013
FROM
Triple Analysis: Breast Cancer, Prostate Cancer and Peptides Triple Analysis: Breast Cancer, Prostate Cancer and Peptides - Product Thumbnail Image

Triple Analysis: Breast Cancer, Prostate Cancer and Peptides

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Prostate Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated...

January 2013
FROM
Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Peptides Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Peptides - Product Thumbnail Image

Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific...

January 2013
FROM
Loading Indicator

Our Clients

Our clients' logos